BDRX · Biodexa Pharmaceuticals Plc

This filing discloses a material, board-driven share capital reorganization intended to resolve operational inefficiencies stemming from Biodexa’s extraordinarily high share count — 373.057 billion ordinary shares of £0.000001 nominal value. The Board explicitly states this structure creates 'unnecessary complexity in the administration and reporting of the Company’s share capital and in the processing of corporate actions.' The proposed remedy is a two-step mechanical restructuring: first, a 10,000:1 reverse split consolidating existing shares into 37.3 million Consolidated Ordinary Shares of £0.01 nominal value; second, subdividing each Consolidated Share into one New Ordinary Share (retaining identical rights) and 9,999 E deferred shares. Critically, the reorganization is designed to preserve aggregate nominal value and proportionate economic ownership — confirmed by the simultaneous adjustment of the ADS ratio from 500,000:1 to 50:1, maintaining the exact same ~746,113 ADSs outstanding. The creation of E deferred shares — which confer no voting rights, dividends, or distributions, and are subject to cancellation without compensation — serves purely as an accounting mechanism to absorb the nominal value reallocation while avoiding changes to the equity structure’s economic substance. Because Resolutions 8 and 11 are inter-conditional and Resolution 11 requires a 75% supermajority, failure of either would halt the entire reorganization, leaving the current capital structure intact. For investors, the primary significance lies not in economic impact — which is intentionally neutral — but in governance execution risk and the signal that the Board prioritizes administrative scalability ahead of maintaining status quo capital architecture. The reorganization also triggers procedural consequences, including fractional share handling (aggregation and sale), warrant/option adjustments, and mandatory updates to the Company’s articles — all of which are fully disclosed but carry no forward-looking financial implications.